HIV Protease Inhibitor Use During Pregnancy Is Associated With Decreased Progesterone Levels, Suggesting a Potential Mechanism Contributing to Fetal Growth Restriction

Background. Protease inhibitor (PI)–based combination antiretroviral therapy (cART) is administered during pregnancy to prevent perinatal human immunodeficiency virus (HIV) transmission. However, PI use has been associated with adverse birth outcomes, including preterm delivery and small-for-gestati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Infect Dis
Autors principals: Papp, Eszter, Mohammadi, Hakimeh, Loutfy, Mona R., Yudin, Mark H., Murphy, Kellie E., Walmsley, Sharon L., Shah, Rajiv, MacGillivray, Jay, Silverman, Michael, Serghides, Lena
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2015
Matèries:
Major Articles and Brief Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4264589/
https://ncbi.nlm.nih.gov/pubmed/25030058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiu393
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars